AXA Framlington Biotech Fund - Z Accumulation
Category Sector Equity Biotechnology
This fund can be held in an Investment ISA, SIPP and Investment Account
Last buy/sell price
640.60p
1.50p (+0.23%)
Fund Code
FMBTA
B784NS1
GB00B784NS11
Prices updated as at 12 Dec 2025
Prices in GBX
Investment objective
The aim of this Fund is to provide long-term capital growth over a period of 5 years or more. The Fund invests in shares of listed companies, principally in the biotechnology, genomic and medical research industry, which the Manager believes will provide above-average returns. The Fund invests in companies of any size which can be based anywhere in the world, albeit the Fund tends to be biased towards the US as this is where the majority of biotechnology companies are based. The Manager selects shares based upon analysis of a company’s financial status, quality of its management, expected profitability and prospects for growth.
Important documents: Please ensure that you have read the Key Information Document/Technical Guide
, SDR Consumer facing disclosure, Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and the fund information documents. These can be found within the Charges & documents section.
- Key stats
- Growth
- Performance
- Charges & documents
- Dividends
- Portfolio
- Risk & rating
- Management
Company name
AXA Investment Managers UK Ltd
Fund launch date
26 Nov 2001
Domicile
United Kingdom
UCITS
Yes
Lead manager
Chris Eccles
Lead manager start date
29 Mar 2024
Lead fund manager biography
Chris Eccles is a research analyst who specialises in testing and regulatory affairs. He researches stocks globally and focuses on the Healthcare sector.
Chris joined Impax in March 2019. He started working in the financial industry in 2011 as a research analyst at Morgan Stanley where he focused on European large-cap pharmaceuticals. In 2014, he became a partner at the hedge fund Kola Capital where he worked as a global equities analyst for three years before moving to Stifel in 2017 to work as a Healthcare Specialist.
Chris achieved an MA (Oxon) Physiological Sciences First Class Honours, from the University of Oxford.
Lead manager
Cinney Zhang
Lead manager start date
29 Mar 2024
Lead fund manager biography
Head office
22 Bishopsgate
London
United Kingdom
EC2N 4BQ
Got a question?
Get in touch
we're here to help:
44 20 7003 2345
Mon-Fri 8am to 6pm